Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Children born to men taking valproate at increased risk of neurodevelopmental disorders

Children born to men taking valproate at increased risk of neurodevelopmental disorders

Patients should not stop taking their anti-seizure medicine without advice from their healthcare professional

The Medicine and Healthcare products Regulatory Agency (MHRA) has cautioned men on valproate to talk to their healthcare professional about their treatment, if they want to start a family in the next year.


The warning came after a new study, commissioned by the European Medicines Agency, suggested that children fathered by men who took the anti-seizure medicine in the three months prior to conception may be at higher risk of developing neurodevelopmental disorders.

Around five in 100 children born to fathers treated with valproate around conception were diagnosed with a neurodevelopmental disorder, compared to three in 100 children whose fathers were taking other antiseizure medicines (lamotrigine or levetiracetam).

However, the risk is believed to be much smaller than the risk associated with valproate in pregnancy.

The revised study results are being reviewed by the MHRA as part of their ongoing monitoring of the safety of valproate.

The health regulator said it will be seeking independent expert advice from the Commission on Human Medicines, and any further guidance will be communicated to patients and healthcare professionals.

In November 2023, the MHRA issued a Valproate National Patient Safety Alert warning that the drug may cause serious harm to the baby, if taken during pregnancy, and lead to impaired fertility in males.

Health organisations were also instructed to prepare for new regulatory measures to reduce the serious harms of valproate.

As per the new measures, expected to be introduced later in January, valproate must not be started in new patients (male or female) younger than 55 years, unless “there is no other effective or tolerated treatment, or there are compelling reasons that the reproductive risks do not apply.”

Patients are informed that they should not stop taking valproate without advice from their healthcare professional, and those who have concerns are encouraged to talk to their doctor.

More For You

Call to improve inclusivity in clinical research

Ethnic minority adults continue to be underrepresented in clinical trials.

iStock

Call to improve inclusivity in clinical research

A NEW report has called for the participation of a wide range of diverse communities in clinical research to make sure that the medicines meet the needs of the UK's increasingly diverse population.

The report ‘Achieving inclusivity in clinical research’, prepared by the Association of the British Pharmaceutical Industry (ABPI) and the Association of Medical Research Charities (AMRC), highlights the long-standing challenges in ensuring diversity in clinical trials.

Keep ReadingShow less
Pharmacy students Learning Support Fund

Pharmacy students will be included in the Travel and Dual Accommodation Expenses section of the NHS Learning Support Fund.

iStock

Pharmacy students to have access to Learning Support Fund

FOR the first time in England, pharmacy students will be eligible to reimburse travel and accommodation costs while attending placements.

The Department of Health and Social Care confirmed that pharmacy students would finally be included in the Travel and Dual Accommodation Expenses (TDAE) section of the NHS Learning Support Fund (LSF).

Keep ReadingShow less
NHS for robotic surgery

Patients undergoing robotic surgery are able to recover quicker and be discharged sooner.

Pic credit: iStock

NHS pushes for robotic surgery to reduce waiting time, improve outcomes

The NHS is planning to step up robotic surgery over the next decade to reduce waiting time, help in the speed of recovery of patients, and shorter hospital stay.

As per the NHS projections, the number is expected to zoom from 70,000 in 2023/24 to half a million by 2035.

Keep ReadingShow less
Scotland's digital patient care record

The amendment ensures that every person who receives health care or a social service in Scotland will have a digital care record

Pic credit: iStock

Scotland's move to create digital patient care record hailed

The Royal Pharmaceutical Society (RPS) in Scotland has welcomed the decision of the Scottish Parliament to create an integrated digital patient care record.

The move came during a debate on the Care Reform (Scotland) Bill on Tuesday (10), when Jackie Baillie tabled an amendment to ensure that every person who receives health care or a social service in Scotland has a digital care record.

Keep ReadingShow less
A woman using a period tracker app

Cambridge University academics have flagged concerns over the safety of period tracker apps

Pic credit: iStock

Users of period tracking apps face privacy, safety risk, say experts

The report said the apps provide a "gold mine" of data for consumer profiling and warn that in the wrong hands it could pose a safety risk

CAMBRIDGE UNIVERSITY academics have flagged concerns over the safety of period tracker apps and warned that the women using them could face privacy and safety risks.

Keep ReadingShow less